Menu Menu Menu
Nice Insight Research
Content Menu
Menu Menu Menu
To Top

Search By Topic

Contract Development and Manufacturing (CDMO)

433 Articles available
Parenterals

A Risk Analysis Approach to Producing Environmentally Sensitive Parenterals

PA0-M06-18-CL-007
Regulatory

Reducing Time to Market with Targeted Regulatory Affairs Support

PAO-06-18-CL-003
Clinical Data

Novartis JULIET trial of Kymriah demonstrates more than one-year durability of responses in adults with relapsed or refractory DLBCL

PR-M06-18-NI-062
Cell and Gene Therapy

StrideBio Closes $15.7 Million Series A Financing to Advance Transformational AAV Platform

PR-M06-18-NI-054
FDA

Statement from FDA Commissioner Scott Gottlieb, M.D., on new efforts to advance medical product communications to support drug competition and value-based health care

PR-M06-18-NI-048
Commercial Supply

Alcami's Extended Workbench Supports Commercial Supply of Flexion Therapeutics's ZILRETTA® (triamcinolone acetonide extended-release injectable suspension)

PR-M06-18-NI-047
Hot Melt Extrusion

Leveraging Hot Melt Extrusion for Solubility and Continuous Manufacturing

PAP-Q2-18-CL-007
Acquisition

Alcami to Become Industry Leading Platform CDMO Following Acquisition by Madison Dearborn Partners

PR-M06-18-NI-021
Acquisition

Avara Pharmaceutical Services Acquires Major Sterile Manufacturing Facility and Development Center in Canada

PR-M05-18-NI-121
Mergers & Acquisitions

Inside Mergers & Acquisitions

PAP-Q2-18-CL-001
Biologic Candidates

Addressing Development Challenges for Complex Biologic Drug Candidates

PAP-Q2-18-CL-004
Contract Manufacturing Needs

Meeting Biopharma Contract Manufacturing Needs with a Flexible  Global Network

PAP-Q2-18-CL-006
Biologics

Building a Biologics Business from the Ground Up

PAP-Q2-18-CL-008
Multi-Product Facility Manufacturing

Using a Risk-Based Approach to Manufacturing in a Multi-Product Facility

PAP-Q2-18-CL-009
GMP

State-of-the-Art Biologics Manufacturing in an Unexpected Location

PAP-Q2-18-CL-010
Cell and Gene Therapy

Overcoming Raw Material and Supply Chain Challenges in Viral Vector Manufacturing

PAP-Q2-18-CL-011
OSD Facility Design

Modern OSD Facility Design Considerations for Operational Efficiency and Regulatory Compliance

PAP-Q2-18-CL-012
Corporate Social Responsibility

Corporate Social Responsibility as a Driver for Improved Sustainability

PAP-Q2-18-CL-014
Oral Peptides

Scientific Expertise Facilitates Oral Peptide Product Development and Manufacturing

PAP-Q2-18-CL-017
Market Expansion

BioPharma CDMO Success Requires Technical Leadership and Problem-Solving Capabilities

PAP-Q2-18-CL-019
Drug Discovery

TEVA Hopes to Launch New Migraine Drug Immediately After PDUFA Date

PAO-M05-18-NI-020
Novel Medicine

WuXi Laboratory Testing Division: Propelling Innovation and Better Treatments for Patients

PAO-M05-18-CL-004
FDA

New WuXi STA Solid-Dose API Plant Gets Okay from US FDA

PAO-M05-18-NI-004
Announcement

Alcami St. Louis Facility to be Honored by Missouri House of Representatives and City of St. Louis

PR-M05-18-NI-032
Drug Development

Praxbind®, Specific Reversal Agent for Pradaxa®, Now Available in 3,200 Hospitals Nationwide

PR-M05-18-NI-034
Announcement

Sanofi Named to DiversityInc's Top 50 Companies for Diversity®

PR-M05-18-NI-031
Drug Discovery

Bactevo Enters Drug Discovery Agreement with Boehringer Ingelheim

PR-M05-18-NI-024
Patient Adherence

New Approach by Novo Nordisk Ties Pricing to Patient Behavior

PAO-M04-18-NI-017
Expanded Capacity

Avara Pharmaceutical Services Hold Groundbreaking at New Aiken Site

PR-M04-18-NI-86
Awards

WuXi Biologics Wins CMO Leadership Award from Life Science Leader Magazine

PR-M04-18-NI-73
Donation

Grifols Donates Over 25 million International Units of Blood Clotting Factor in 2017

PR-M04-18-NI-70
Approval

Fresenius Kabi Announces New Approval and Immediate Availability of Daptomycin for Injection

PR-M04-18-NI-58
Drug Delivery

Allergan Announces Launch of the TrueTear® Intranasal Neurostimulation Device During 2018 ASCRS-ASOA Annual Meeting

PR-M04-18-NI-55
CDMO

European Commission Approves Expanded Indication For Amgen's XGEVA® (denosumab) For The Prevention Of Skeletal-Related Events In Patients With Multiple Myeloma

PR-M04-18-NI-021
Expanded Capacity

AGC Biologics Increases Footprint in Bothell, WA

PR-M04-18-NI-016
Probiotics

J&J Involved in Probiotics Development Program

PR-M03-18-NI-100
Operational Excellence

Transforming A CDMO Using an Operational Excellence Approach

PAO-M03-18-CL-003
Award

Piramal Pharma Solutions Wins in Six Categories at the 'CMO Leadership Awards 2018'

PR-M03-18-NI-099
Drug Development

More Good News for Novo Nordisk’s Semaglutide and Weight Loss

PAO-M03-18-NI-024
Production

LANXESS Starts Production Line for Specialty Compounds in Germany

PAO-M03-18-NI-022
Influenza

Anti-Flu Drug Exploits Weakness in H3N2 Strain

PAO-M03-18-NI-021
Oncology

Tumor Derived T cells Demonstrate Potential Against Ovarian Cancer

PAO-M03-18-NI-020
Expanded Capacity

Hovione Reports on Recent Capacity Expansion and Future Plans to Support Growth

PR-M03-18-NI-081
DCAT

DSM Sinochem Pharmaceuticals hosts second “public-private dialogue on combating Antimicrobial Resistance” during DCAT week

PR-M03-18-NI-072
Donation

Alcami Donation to Outfit TROSA Medical Department

PR-M03-18-NI-065
Acquistion

Siegfried Purchases the Drug Product Manufacturing Facility of Arena Pharmaceuticals GmbH in Zofingen

PR-M03-18-NI-058
Approval

European Commission Expands Marketing Approval for GSK’s Relvar Ellipta

PAO-M03-18-NI-013
Cell Line

Abzena Strengthens Specialized Bioassay Offering Through Access Agreement with Major Cell Line Depository

PR-M03-18-NI-053
M&A Activity

M&A Activity in a Fragmented CDMO Market

PAP-Q1-18-NI-001
Serialization

Facilitating Implementation and Customer Service with Offline Serialization

PAP-Q1-18-CL-005
Strategic Collaboration

Driving Change in the Pharma Industry and Biotech One Relationship at a Time

PAP-Q1-18-CL-004
Industry

Why Business Continuity Management is Important for CDMOs

PAP-Q1-18-CL-003
Fill/Finish

Getting to the Finish Line

PAP-Q1-18-NI-004
Sponsor

What’s Driving M&A Among Pharma Sponsors?

PAP-Q1-18-NI-003
Capsules

Overcoming Formulation Challenges with Liquid-fill Capsules

PAP-Q1-18-CL-004
Pharmageddon

Uniting the Industry for the Prevention of “Pharmageddon”

PAP-Q1-18-CL-001
Formulation

Investing in New Technologies for Innovative Functional Solutions

PAP-Q1-18-CL-009
Injectables

Meet Chemo CMO: Preferred Partner for Injectables Manufacturing

PAP-Q1-18-CL-015
Biologics

Fully Supporting Customer Needs for Biologics Development and Manufacturing

PAP-Q1-18-CL-016
API Manufacturing

Meeting the Need for Small-Volume API Manufacturing

PAP-Q1-18-CL-016
Fermentation

Focused on Fermentation

PAP-Q1-18-CL-007
Business

DSM Sinochem Pharmaceuticals Is for Sale

PAO-M03-18-NI-009
Expanded Capacity

Catalent Completes $4.6 Million Expansion at Singapore Clinical Supply Facility

PR-M03-18-NI-008
License Agreement

Xencor Signs Four Commercial License Agreements with Selexis SA to Advance its Pipeline of XmAb Bispecific Antibody Drug Candidates

PR-M03-18-NI-009
Innovation

Thermo Fisher Supplies Analytical Instruments to World Anti-Doping Agency Laboratory in South Korea

PR-M03-18-NI-011
Facility

First Order Reported for New Samsung Plant

PAO-M03-18-NI-001
Drug Delivery

Amgen Receives Positive CHMP Opinion For Delivery System Of Neulasta® (pegfilgrastim)

PR-M03-18-NI-002
Innovation

Thermo Fisher Scientific Innovations Offer Greater Connectivity and Ease of Use

PR-M03-18-NI-005
Cell and Gene Therapy

Brammer Bio Supports Rare Disease Day 2018

PR-M03-18-NI-006
FDA

WuXi Biologics Congratulates MabSpace on FDA Clearance of IND for MSB2311

PR-M03-18-NI-001
NDA

FDA Acceptance of Medicines360's Filing for supplemental New Drug Application for LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg

PR-M02-18-NI-108
FDA Acceptance

Mallinckrodt Receives FDA Acceptance of Stannsoporfin New Drug Application Filing

PR-M02-18-NI-106
Expanded Capacity

LANXESS expands capacity for Macrolex dyes at its Leverkusen site

PR-M02-18-NI-104
Agreement

Abarca, Amgen Enter Outcomes-Based Agreement For Repatha® (evolocumab)

PR-M02-18-NI-103
Expanded Capacity

CapsCanada Expands K-CAPS®(HPMC Capsules) Manufacturing Capacity for Second Time

PR-M02-18-NI-109
CDMO

Servier Reports Year-On-Year Growth

PAO-M02-18-NI-024
Drug Development

HEPAXA is a New Treatment in the US from BASF for Patients with NAFLD

PAO-M02-18-NI-023
Drug Development

Amgen Receives Positive Opinion Expanding Use Of XGEVA® (denosumab) To Cover Prevention Of Skeletal-Related Events In Patients With Multiple Myeloma In Europe

PR-M02-18-NI-102
Innovation

LYNPARZA® (olaparib) Receives Positive EU CHMP Opinion in Platinum-Sensitive Relapsed Ovarian Cancer

PR-M02-18-NI-100
Clinical Data

Bayer Announces Publication of Larotrectinib Data in The New England Journal of Medicine

PR-M02-18-NI-97
Vaccine

AstraZeneca Announces Renewed Recommendation and Availability of FLUMIST QUADRIVALENT Vaccine in the US

PR-M02-18-NI-96
Analytical Services

AMRI to Expand Container Closure Integrity Testing Services (CCIT) into European Union

PR-M02-18-NI-94
Combination Treatment

Mylan Receives Tentative Approval for Combination HIV Treatment DTG/FTC/TAF Under FDA's PEPFAR Program

PR-M02-18-NI-92
Drug Development

Kidney Disease Drug Licensed to AstraZeneca

PAO-M02-18-NI-022
Robotics

Johnson & Johnson Medical Devices Companies Acquire Orthotaxy to Develop Next-Generation Robotic-Assisted Surgery Platform in Orthopaedics

PR-M02-18-NI-91
Generics

Perrigo Confirms Patent Challenge For Generic Version Of Finacea® Foam, 15%

PR-M02-18-NI-90
Clinical Trials

Aimmune’s AR101 Meets Phase 3 Endpoints

PAO-M02-18-NI-020
Appointment

Catalent Announces Changes to its Board of Directors

PR-M02-18-NI-84
Clinical Trials

AbbVie Announces New Phase 2 Data for Upadacitinib Showing Clinical and Endoscopic Outcomes in Crohn's Disease at 52 Weeks

PR-M02-18-NI-83
Drug Development

Evotec and MaRS Innovation Announce First Funded Project under LAB150 Bridge

PR-M02-18-NI-79
Clinical Trials

Breakthrough Scar Treatment in Clinical Trials

PAO-M02-18-NI-016
Strategic Collaboration

Bristol-Myers Squibb and Nektar Therapeutics Announce Global Development & Commercialization Collaboration for Nektar’s CD122-biased Agonist, NKTR-214

PR-M02-18-NI-73
Approval

Celltrion Receives EU Approval for Trastuzumab Biosimilar

PR-M02-18-NI-71
Cell Culture Portfolio

Lonza Expands Cell-Culture Portfolio with Quasi Vivo ® System

PR-M02-18-NI-59
SCRS' Global Impact Partner Program

Boehringer Ingelheim Demonstrates their Commitment to Site Relationships by Joining SCRS' Global Impact Partner Program

PR-M02-18-NI-56
Dermatology

Sun Pharma Announces Twelve Tildrakizumab Abstracts to be Presented at American Academy of Dermatology 2018 Annual Meeting

PR-M02-18-NI-54
Strategic Collaboration

Sirenas Enters Into Multi-Target Collaboration With Bristol-Myers Squibb

PR-M02-18-NI-55
Inhalation

Teva Announces U.S. Launch of QVAR® RediHaler™ (Beclomethasone Dipropionate HFA) Inhalation Aerosol

PR-M02-18-NI-53
Growth

Fueled by Growth, Alcami Unveils New Sales Office in Cambridge, MA

PR-M02-18-NI-63
Strategic Partnership

ImmunoQure AG and Servier Enter into Strategic Partnership for the Development of an Interferon-alpha Human Autoantibody

PR-M02-18-NI-64
Acquistion

LANXESS successfully completes acquisition of Solvay’s phosphorus additive business

PR-M02-18-NI-051
Generics

Teva Announces Launch of a Generic Version of Syprine® in the United States

PR-M02-18-NI-050
FDA Approval

Pii and Its Partners Received FDA Market Approval for Seven Products and Commercially Launched 6 Products in 2017

PR-M02-18-NI-048
Strategic Partnership

Denali Therapeutics and Lonza Pharma & Biotech Announce Exclusive Partnership to Develop and Produce Biologic Medicines

PR-M02-18-NI-047
Acquistion

Allergen Acquires Elastagen

PAO-M02-18-NI-012
Launch

WuXi AppTec Launches Advanced Library Compound Initiative on LabNetwork.com

PR-M02-18-NI-039
Award

Thermo Fisher Scientific Wins CiteAb 2018 Award for its Antibody Validation Initiative

PR-M02-18-NI-040
Strategic Partnership

AbbVie and MBC BioLabs Team Up to Support Life-Science Startups in the San Francisco Bay Area

PR-M02-18-NI-037
Clinical Trials

Tyzivumab is Ready for Trials

PAO-M02-18-NI-011
Biomanufacturing

Amgen to Open Biomanufacturing Plant in the US

PAO-M02-18-NI-010
FDA Approval

Grifols HyperRAB® (rabies immune globulin [human]) 300 IU/mL Receives FDA Approval to Treat Patients Exposed to Rabies Virus Infection

PR-M02-18-NI-036
Packaging

SCHOTT AG, ARaymondlife and Vanrx Pharmasystems announce product compatibility for primary packaging of sterile injectables

PR-M02-18-NI-035
Research

Lonza to Present Latest Research into More Physiologically Relevant ADME-Tox Models at the Society of Toxicology Meeting

PR-M02-18-NI-034
Marketing

Evonik Launches a New MetAMINO® Marketing Campaign to the Middle East and African Markets At VIV MEA in Abu Dhabi

PR-M02-18-NI-033
Launch

Thermo Fisher Scientific Launches Axiom Microbiome Array for Research

PR-M02-18-NI-032
Acquistion

Celanese Completes Omni Acquisition

PAO-M02-18-NI-009
Investment

Polpharma Group Gets Digital

PAO-M02-18-NI-008
CDMO

Grünenthal Group Receives FDA's Expedited Access Pathway Designation for VIVO

PR-M02-18-NI-030
Acquistion

Celgene Corporation Commences Tender Offer for Juno Therapeutics, Inc.

PR-M02-18-NI-026
Generic

Mylan Expands Access to HIV/AIDS Medicines with Launch of First Generic Sustiva® Tablets

PR-M02-18-NI-025
Appointment

PPD Names Maria Teresa Hilado, CFO of Allergan, to its Board of Directors

PR-M02-18-NI-023
Joint Venture

DSM and Evonik Establish Veramaris Joint Venture

PR-M02-18-NI-024
Acquistion

Partner Therapeutics (PTx) Acquires Leukine® from Sanofi

PR-M02-18-NI-021
Investment

Dracen Pharmaceuticals Raises Over $40 million

PAO-M02-18-NI-007
Drug Development

Mylan and Theravance Will Receive FDA Decision on COPD Drug by November

PAO-M02-18-NI-006
Immuno-Oncology

Syndax Announces Immuno-Oncology Clinical Trial Collaboration with AstraZeneca

PR-M02-18-NI-020
Clinical Trials

Novartis Announces NEJM Publication Of Updated Analysis From ELIANA Trial Showing Longer-Term Durable Remissions With Kymriah™ In Children, Young Adults With r/r ALL

PR-M02-18-NI-019
CEO

Rentschler Biopharma SE Appoints International Biopharma Expert Dr. Ralf Otto as Chief Operating Officer

PR-M02-18-NI-018
Investment

Charles River Laboratories Makes Investments in High-Throughput Screening Infrastructure

PR-M02-18-NI-017
Leadership

Avara Pharmaceutical Services Wins CMO Leadership Awards in All 6 Categories for Contract Manufacturing

PR-M02-18-NI-016
Expanded Capacity

Cambrex Expands Process Research and Development Capabilities Across North America

PR-M02-18-NI-014
IND Application

WuXi Biologics Congratulates BioAtla on FDA Clearance of IND Application for CAB-AXL-ADC

PR-M02-18-NI-011
Healthcare

Leading Companies Taking Action to Address Healthcare

PAO-M02-18-NI-005
Animal Nutrition

Versamaris JV Formed by DSM and Evonik

PAO-M02-18-NI-004
Oncology

Stand Up To Cancer Announces $11M Collaborative, Multi-Disciplinary Research Program

PR-M02-18-NI-010
Partnership

Agilent Partners with Science Exchange

PR-M02-18-NI-009
Strategic Collaboration

WuXi Biologics and Aravive Biologics to Form Strategic Manufacturing Collaboration Following Successful IND Filing for AVB-S6-500

PR-M02-18-NI-007
Agreement

BioDuro Announces Cooperation Agreement with Porton Pharma Solutions

PR-M02-18-NI-006
Fast Track

FDA Grants Fast Track Status to Takeda’s Zika Vaccine Candidate

PAO-M02-18-NI-003
New Drug Application

Theravance Biopharma and Mylan Announce FDA Acceptance of New Drug Application for Revefenacin (TD-4208) in Adults with Chronic Obstructive Pulmonary Disease

PR-M02-18-NI-005
×